NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. (NAMS) focuses on developing therapies for metabolic diseases, including obicetrapib for cardiovascular and Alzheimer's diseases. With a market cap of 2.671B, it reported a -2.35% change at close, trading at 24.95 USD. The company, based in the Netherlands, has 62 full-time employees and is in the biotechnology sector.

Annexon, Inc. appointed William 'BJ' Jones to its board. With 30 years in biotech, Jones has led successful product launches at major firms and currently serves as chief commercial officer at NewAmsterdam Pharma. A Stanford MBA and Texas A&M MS holder, he also serves on Apogee Therapeutics' board.

NewAmsterdam Pharma updates on obicetrapib's clinical development, targeting LDL-C lowering therapies for cardiovascular disease patients. Plans include Phase 3 trial data announcements, studies on obicetrapib's effects, and commercial manufacturing readiness for potential U.S. and European launches.

NewAmsterdam Pharma updates on obicetrapib's clinical development, highlighting 2024 achievements including positive Phase 3 trial results. Plans for 2025 include additional data presentations, regulatory filings, and commercial readiness, supported by a strong financial position. Obicetrapib aims to address unmet needs in cardiovascular disease treatment.

NewAmsterdam Pharma reported 2024 successes with Phase 3 trials for obicetrapib, targeting LDL-C reduction and cardiovascular risk. Plans include advancing trials in 2025 and preparing for U.S. and Europe launches, backed by solid finances. Focused on oral, non-statin treatments for high LDL-C patients.

Annexon, Inc. appointed William “BJ” Jones to its board, leveraging his 30 years of biotech industry experience. Jones's expertise in commercial strategies and product launches is expected to aid Annexon's therapies for neuroinflammatory diseases. He has a history of successful roles in major pharmaceutical companies and currently serves as chief commercial officer at NewAmsterdam Pharma.

NewAmsterdam Pharma updates on obicetrapib's clinical development, highlighting 2025 data presentations from BROADWAY, BROOKLYN, TANDEM, and Phase 2 VINCENT trials. Plans include EMA submission, manufacturing capacity establishment, and inventory build-out. Ended 2024 with $835M cash balance. Obicetrapib aims to lower LDL-C in CVD patients inadequately served by current therapies.